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Abstract.  The structure of rat brain-derived neuro- 
trophic factor (BDNF) gene is complex; four 5' exons 
are linked to separate promoters and one 3' exon is 
encoding the BDNF protein. To analyze the relative 
importance of the regulatory regions in vivo, we have 
generated transgenic mice with six different promoter 
constructs of the BDNF gene fused to the chloram- 
phenicol acetyl transferase reporter gene. High level 
and neuronal expression of the reporter gene, that in 
many respects recapitulated BDNF gene expression, 
was achieved by using 9 kb of genomic sequences 
covering the promoter regions that lie adjacent to each 
other in the genome (promoters I and II and promoters 
HI and IV, respectively) and by including sequences of 
BDNF intron-exon splice junctions and 3' untranslated 
region in the constructs. The genomic regions respon- 
sible for the in vivo upregulation of BDNF expression 
in the axotomized sciatic nerve and in the brain after 
kainic acid-induced seizures and KCl-induced spread- 
tug depression were mapped. These data show that 
regulation of the different aspects of BDNF expression 
is controlled by different regions in vivo, and they sug- 
gest that these promoter constructs may be useful for 
targeted expression of heterologous genes to specific 
regions of the central and peripheral nervous systems 
in an inducible manner. 
B 
RAin-derived neurotrophic  factor (BDNF) ~ (Barde et 
al., 1982; Leibrock et al., 1989) is a member of the 
neurotrophin family that includes three other struc- 
turally  related proteins:  NGF,  neurotrophin-3,  and  neu- 
rotrophin-4  (reviewed in Korsching,  1993; Persson,  1993). 
In cell culture, BDNF promotes the survival of retinal gan- 
glion cells (Johnson et al., 1986), basal forebrain cholinergic 
neurons (Alderson et al., 1990), embryonic mesencephalic 
dopaminergic neurons (Hyman et al.,  1991; Kniisel et al., 
1991), and embryonic cerebellar granule neurons (Segal et 
al., 1992). BDNF also promotes neuronal differentiation in 
neural crest cell cultures (Sieber-Blum,  199D and enhances 
early maturational  change in dorsal root ganglion cell cul- 
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rares (Wright et al., 1992). Recently, it was shown that en- 
dogenous BDNF is atrophic factor in activity-mediated neu- 
ronal survival of cultured embryonic cortical neurons (Ghosh 
et al.,  1994). In vivo BDNF increases the survival of em- 
bryonic neurons in the dorsal root ganglia,  nodose ganglia 
(Hofer and Barde,  1988), basal forebrain cholinergic neu- 
rons (Kntisel et al.,  1992), as well as developing and ax- 
otomized motoneurons (Oppenheimet al.,  1992; Sendtner 
et al., 1992; Yan et al., 1992; Koliatsos et al., 1993). BDNF 
null-mutated  mice develop several sensory deficits, but no 
obvious defects were seen for motoneurons or central do- 
paminergic neurons  (Ernfors et  al.,  1994; Jones et  al., 
1994). 
Except for the striatum and septum, BDNF mRNA is ex- 
pressed in neurons throughout the adult rat brain with the 
highest level in the hippocampal  formation (Ernfors et al., 
1990a, b; Hofer et al., 1990; Phillips et al., 1990; Wetmore 
et al., 1990), where also BDNF-like immunoreactivity has 
been demonstrated 0Vetmore et al.,  1991). Glutamatergic, 
GABA-ergic, and cholinergic neurotransmitter systems have 
been shown to be involved in the regulation of  BDNF mRNA 
expression (Zafra et al.,  1990, 1991; Ernfors et al.,  1991; 
Isackson et al., 1991; Dugich-Djordejevic  et al.,  1992a, b; 
Lindefors et al., 1992; Lindvall et al.,  1992). Activation of 
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types has been implicated in the increase of BDNF mRNA 
after administration  of kainlc acid (KA) or after epileptic and 
ischemic insults  (Zafra et al.,  1990,  1991;  Ernfors et al., 
1991; Lindvall et al., 1992). However, the molecular mecha- 
nisms governing the increase of BDNF mRNA levels, as well 
as the mechanisms responsible for the tissue-specific and de- 
velopmentally  regulated expression of BDNF  mRNA,  are 
unknown. 
It has recently been shown that the organization of BDNF 
gene is complex (Tunmusk et al., 1993). Four short untrans- 
lated 5' exons and one 3' exon encoding the mature BDNF 
protein are present within the rat BDNF gene with a separate 
promoter upstream of each 5' exon. Alternative promoter us- 
age, differential splicing and the use of two different polyade- 
nylation  sites  within  each  of the  four  transcription  units 
generate altogether eight different BDNF mRNAs (Tunmusk 
et al., 1993). Promoters I-HI are used predominantly in the 
brain, while promoter IV is more active in peripheral tis- 
sues.  Moreover,  the  levels of BDNF  mRNAs  transcribed 
from promoters I-HI are markedly elevated in a promoter- 
specific subset of hippocampal and neocortical neurons in 
different models of neuronal activation, while only a modest 
increase was seen for promoter IV specific mRNA (Falken- 
berg et al., 1993; Metsis et al., 1993; Timmusk et al., 1993; 
Kokaia et al.,  1994). 
In this report, we have analyzed the potential of the pro- 
moter regions of the rat BDNF gene to drive expression of 
a reporter gene in transgenic mice. Tissue-specific and high 
level expression of the bacterial reporter gene chioramphenl- 
col  acetyl  transferase  (CAT) in correct  neuronal  populations 
of transgenic  mice brain was achieved by using 9 kb of 
genomic sequences covering the promoter regions that  lic 
close  in the genome (promoters I and II and promoters HI 
and IV, respectively)  and by including  sequences of  BDNF 
introns  with splice  donor and acceptor sites  and 3'  untrans- 
lated  region  (UTR) in  the  constructs.  We also  identified  the 
promoter  regions  that  are  involved  in  the  regulation  of  BDNF 
induction  in different  experimental models, i.e.,  (a) in the 
cerebral  cortex  after  KCl-induced  cortical  spreading  depres- 
sion;  (b)  in the hippocampus and cerebral  cortex  after  KA- 
induced seizures;  and (c) in the axotomized sciatic  nerve. 
Materials and Methods 
General Methods 
All molecular biology procedures were performed according to standard 
practices (Sambrook et ai., 1989).  Plasmid DNA was purified by alkaline 
lysis and CsCI centrifugation. Labeling of cRNA and cDNA probes, RNA 
isolation, CAT assays, RNase protection assay, RNA quantification, and in 
situ hybridization were performed as shown earlier (Thnmusk et ul., 1993, 
1994a).  BDNF exon-specific  cRNA  probes  were  synthesized  from the same 
fragments of rat BDNF gene as described (Timmttsk ct al., 1993,  1994a). 
As a probe for CAT, the 0.8-kb coding sequence of it was digested out from 
pBLCAT2 (Luckow and Schutz, 1987) using XhoH restriction enzyme, sub- 
cloned into the Eco RV site of pBSKS vector (Stratagene, La Jolla, CA), 
and used further to synthesize cRNA or cDNA probes. As a  probe for 
mouse BDNF, a 0.34-kb NarI fragment of mouse BDNF cDNA (Hofer et 
al.,  1990)  was used as a template. 
Tmnsgenic Mice 
Transgenic mice were generated and analyzed for transgene integration as 
previously described (Nilsson and Lendahl, 1993).  Vector sequences were 
removed from the BDNF promoter constructs and the transgene was in- 
jected into the male pronucleus of one-cell mouse embryos obtained from 
superovulated Fl(C57BL6 X CBA). Injected eggs were transferred at the 
one- or two-cell stage to the oviducts of pseudoprngnant foster mothers. 
Tail biopsy-derived DNA isolated from the resulting offspring (F0) was 
screened by Southern or dot blot analysis with CAT-specific probe for the 
presence of  the transgene. Different restriction digests were used to identify 
those animals that contained intact copies of  the construct (data not shown). 
The frequencies for transgenicity were between 15 and 50%. As the integra- 
tion of transgene in F0 founders may be chimeric, most of the transgenic 
founders were maintained as lines by breeding them with wild-type mice. 
The analysis of transgene expression and regulation was performed with 
1-2-mo-old FI animals unless specifically noted. 
Animals, Pharmacological Treatments, and Surgery 
Adult male and female transgenic mice (body wt ffi 20-30 g) were used for 
all experiments. Treatment of animals with kainic acid was performed as 
described earlier (Zafra et al.,  1990) and animals were killed 3-6 h after 
the injection. Spreading depression produced by repeated topical applica- 
tion of KCI to the cortical surface of mice during 2 h was performed as de- 
scribed in (Kokaia et al., 1993) and mice were killed after another 2 h. Tran- 
section of sciatic nerve was performed as previously described (Funakoshi 
et al.,  1993).  After all treatments mice were anesthetized with ether and 
decapitated.  The brains,  indicated brain regions, and peripheral organs 
were dissected and immediately frozen on dry ice. 
BDNF-CAT Fusion Genes 
Promoters of BDNT I, H, m, and IV CAT constructs were all inserted into 
modified pBLCAT2  vector, replacing the thymidine kinase promoter by 
cloning into the XbaI and XhoI sites. All these constructs contain SV-40 
small t  intron and SV-40 polyadenylation signals downstream from CAT 
gene. The numbering and restriction enzyme sites is corresponding to the 
published rat BDNF gene sequence (T'munusk ct ul.,  1993). 
BDNF I CAT contains a 2.6-kb EcoRUCIaI fragment of exon I and its 
5' flanking region. The 5' EcoRI site lies 1.5 kb upstream from the BamHI 
site located at the first basepair of rat BDNF gene sequence. The 3' ClaI 
site is located at 937 bp. 
BDNF 11 CAT contains a 3.7-kb EcoRI/AccI fragment of exon 11 and its 
flanking region. This construct has the same 5' end as BDNF I CAT, but 
it extends 1.2 kb to the 3' direction. The 3' AceI site is located at 2,151 bp 
inside of exon II. 
BDNF m  CAT contains a 4.4-kb HindHi/XbaI fragment of exon HI and 
its 5' flanking region. The 5' HindIII site lies 3.5  kb upstream from the 
HinclI site located at the first basepair of rat BDNF gene sequence. The 
3' XbaI site is located at 901 bp. 
BDNF IV CAT contains a 5.5-kb HindiIFBam~ fragment of exon IV 
and its 5' flanking region. This construct has the same 5' end as BDNF HI 
CAT, but it extends 1.1 kb to the 3' direction. The 3' BamIH site is located 
at 2,051  bp inside of exon IV. 
BDNF IV prox CAT contains a 0.9-kb EcoRJ/BamHI fragment of exon 
IV and its 5' flanking region. This construct is a 5' deletion of BDNF IV 
CAT. 
BDNF I +  II CAT and BDNF HI +  IV CAT were cloned in pBSKS and 
they contain the following: (a) Promoter region and the 5' part of the mini- 
intron including splice donor sites: genomic frasments covering the 5' and 
3' flanking regions of exons I and II or exons IlI and IV, respectively. (b) 
3' part of the mini-intron including splice acceptor site: a 0.7-kb genomic 
fragment covering the Y flenking region of exon V (coding exon) including 
10 bp of  exon V (this is the common splice aceeptor region for all the BDNF 
transcripts). This region is common for both minigenes. (c)  CAT 8ene 
(0.7-kb XhoII fragment) without SV-40 small t intron and polyadenylation 
signals. This region is common for both minigenes. (d) 3' UTR including 
polyadenylation signals: 3.2-kb genomic fragment covering BDNF 3' UTR, 
extending 0.1 kb downstream from the end of the 4.2-kb mRNA. This re- 
gion is common for both minigenes. 
BDNF  I  +  II  CAT  promoter region contains a  9.5-kb  BamHI/SalI 
genomic fragment including exons I and II and the flanking regions. The 
5' BamHI site lies ,o6.5 kb upstream from the BamHI site located at the 
first bp of rat BDNF gene sequence. The 3' SalI site lies ,~,0.7 kb down- 
stream from the end of exon H. 
BDNF HI +  IV CAT promoter region contains a 9-kb BamHI/HindHi 
genomic fragment including exons HI and IV and the flank/rig regions. The 
5' BamHI site lies ,o6 kb upstream from the HincH site located at the first 
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from the end of exon IV. 
Results 
Expression of  BDNF Promoter L II, III, and IV CAT 
Constructs in Transgenic Mice 
Functional analysis of the proximal promoter regions of the 
BDNF gene by  ~ransient transfections showed that sequences 
upstream of all four 5' exons promote expression of the CAT 
reporter gene in neuronal and nonneuronal cell lines (Tim- 
musk et al.,  1993).  To analyze the tissue specificity of the 
rat BDNF gene expression in vivo, transgenic mice were 
generated that harbored a chimeric gene composed of one of 
the upstream regions of the 5' exons of rat BDNF gene fused 
to sequences encoding the bacterial enzyme CAT. The con- 
structs (designated BDNF I CAT, BDNF II CAT, BDNF M 
CAT, and BDNF IV CAT) are represented in Fig. 1. All these 
fusion genes contain SV-40 small t intron and SV-40 polyad- 
enylation  signals  downstream of the  CAT  coding  region. 
BDNF I CAT contains a 2.6-kb fragment of exon I  and its 
5' flanking region. BDNF II CAT contains a 3.7 kb fragment 
of exon II and its 5' flanking region. This construct has the 
same 5' end as BDNF I CAT, but it extends 1.2 kb to the 3' 
direction and has the 3' end in exon 1I. BDNF M  CAT con- 
tains a 4.4-kb fragment of exon M  and its 5' flanking region. 
BDNF IV CAT contains a 5.5-kb fragment of exon IV and 
its 5' flanking region. This construct has the same 5' end as 
BDNF M  CAT, but it extends 1.1 kb to the 3' direction ter- 
minating inside exon IV. 
CAT activity was measured in brain and in 10 nonneural 
tissues:  salivary gland,  thymus, heart,  lung,  spleen,  liver, 
kidney, pancreas, muscle, and testis.  As the mouse BDNF 
gene structure has not been reported, the expression patterns 
of the BDNF-CAT fusion genes were compared to the levels 
of rat BDNF mRNAs containing different 5' exons by RNase 
protection assay. 
2.6 kb of  BDNF Promoter I Targets the Expression of 
Reporter Gene to the Thymus of Transgenic Mice 
Eight different transgenic  lines expressing CAT under the 
control of a 2.6-kb 5' flanking sequence of exon I (BDNF I 
CAT) were analyzed. CAT activity was detected in the thy- 
mus of all of the eight lines tested. In the other organs, in- 
cluding the brain, the levels of CAT activity were close to 
or below the detection limit (Fig. 2 and Table I). We have 
recently shown that in the rat this promoter is active in brain 
and not in lung and heart (Tmunusk et al.,  1993).  RNase 
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Figure 1. Schematic representation of rat BDNF-CAT fusion genes 
analyzed in transgenic mice in relation to the rat BDNF gene struc- 
ture. The gene is shown in top with exons with their corresponding 
numbering as boxes and introns as lines. UTRs of the exons are in- 
dicated by open boxes, and the region corresponding to the prepro- 
BDNF protein is indicated by the filled box. Restriction sites for 
BamHI are indicated  by B's.  The BDNF CAT fusion  genes  are 
shown below the schematic map of BDNF gene. Open boxes with 
I, II, HI, IV, IV prox, I +  II, and M  +  IV indicate the upstream 
regions of  BDNF 5' exons included in BDNF I CAT, BDNF II CAT, 
BDNF HI CAT, BDNF IV CAT, BDNF IV prox CAT, BDNF I  + 
il CAT, and BDNF HI + IV CAT, respectively. Broken lines show 
the regions of rat BDNF gene included in the BDNF-CAT fusion 
genes. ~,, SV-40 small t intron and polyadenylation signals. BDNF 
3', 3' UTR of rat BDNF gene. 
Figure 2. Expression of BDNF I CAT (CAT/), BDNF II CAT (CAT 
//), BDNF m  CAT (CATIlI), and BDNF IV CAT (CAT/V) in the 
brain and nonneural  tissues of transgenic mice of representative 
founder lines. 1 mg of protein extract was analyzed in each line by 
CAT assay. Samples were incubated for 2 h at 37°C. Expression of 
endogenous rat BDNF exon mRNAs in the same rat tissues ana- 
lyzed by RNase protection assay is shown in top of the CAT assays 
of each BDNF-CAT fusion gene. 
Timmusk et al.  BDNF Promoters in Transgenic Mice  187 Table I. 7~ssue  Distribution of  CAT  Activity in Transgenic Mice with Different BDNF-CAT  Fusion Genes 
CAT activity  TISSUE 
BRA  SAL  THY  HEA  LUN  SPL  LIV  KID  PAN  MUS  T/O 
I  6  0  8  6  4  6  0  0  0  0  0 
n =  8  (+)  -  +  (+)  (+)  (+)  ..... 
H  4  0  4  0  0  0  0  0  0  0  0 
n  ffi  18  (+)  -  (+)  ........ 
Ill  6  2  4  4  4  4  4  3  3  6  4 
n  =  11  +  (+)  +  +  +  (+)  (+)  (+)  (+)  +  (+) 
IV  11  8  8  8  8  8  8  8  11  8  8 
n  =  13  +  (+)  (+)  (+)  (+)  (+)  (+)  (+)  +  (+)  (+) 
I  +  H  9  m  9  1  7  1  0  1  1  1  1 
n  =  9  +++  ++  (+)  +  (+)  -  (+)  (+)  (+)  (+) 
IH+IV  6  nt  6  2  5  1  1  3  2  2  1 
n  =  6  +  +  +  +  +  (+)  +  (+)  (+)  (+)  (+)  (+)  (+) 
Average conversion of [14C]chloramphenicol  per 1 nag protein during 2 h reaction at 37°C in the expressing founder lines: (+), <1% conversion;  +, 1-5%;  + +, 
5-25%;  + + +, >25%. I, II, HI, IV, I  +  If, and Ill +  IV, BDNF-CAT fusion genes BDNF I CAT, BDNF II CAT, BDNF HI CAT, BDNF IV CAT, BDNF 
I +  H CAT, and BDNF HI +  IV CAT, r~e~vely, n, number of analyzed founder lines; nt, not tested; BRA, brain; SAL, salivary gland; THY, thymus; HEA, 
heart;  LUN, lung; SPL, spleen; L/V, liver; K/D, kidney; PAN, pancreas;  MUS, skeletal muscle;  T/O, testis or ovary. 
protection analysis  of RNA  from  11  different rat tissues 
showed that, in addition to brain, lower levels of BDNF exon 
I  mRNA are expressed in the thymus and spleen (Fig. 2). 
These data demonstrate that the 2.6-kb of 5' flanking BDNF 
exon I  sequence is  sufficient to direct appropriate tissue- 
specific expression of reporter gene in the thymus, but not 
in the spleen and brain. 
~7 kb of  BDNF Promoter H Is Predominantly Silent in 
Transgenic Mice 
18 lines containing CAT under the control of 3.7 kb of the 
5' flanking sequences of BDNF exon II were generated and 
analyzed. In 14 lines, we were not able to detect any CAT 
activity. In the remaining four lines, CAT activity was de- 
tected only in the brain and thymus, and it was significantly 
lower than i~ the thymus of transgenic mice carrying the 
BDNF I CAT transgene.  (Fig. 2 and Table I). RNase pro- 
tection  analysis  revealed  that  the  endogenous expression 
of BDNF exon II mRNA in rat is restricted to the brain 
(Fig. 2). The 3.7-kb of BDNF exon II 5' flanking region is 
apparently lacking positive regulatory sequences that are 
regulating the endogenous BDNF mRNA expression from 
this promoter. 
4.4 kb of  BDNF Promoter I11 Directs CAT Expression 
Predominantly in Brain and Muscle 
11 different founder lines carrying 4.4 kb of the upstream se- 
quences of  BDNF exon IT[ linked to CAT gene were analyzed 
and in six of them CAT activity was detected (Table I). In 
two lines, CAT activity was highest in the muscle and brain, 
and lower levels were present in the lung, thymus, heart, and 
liver (representative founder line is shown in Fig. 2). In two 
other lines, CAT activity was detected only in the muscle and 
brain. In two fines, CAT activity was detected in most of the 
organs with little differences in the expression levels. In five 
lines, we did not detect CAT activity in any of the analyzed 
organs. In the rat, this promoter is active mainly in brain and 
less also in the heart, as revealed by Northern blotting (Tim- 
musk et al.,  1993). RNase protection analysis of 11 rat tis- 
sues  confirmed that the highest levels of BDNF exon 11I 
mRNA are present in the brain and significantly lower levels 
were seen in heart.  Exon llI mRNA was also detected in 
muscle  and  lung  at  low  (close to  detection limit)  levels 
(Fig. 2). Taken together, the results demonstrate that the 4.4- 
kb of  BDNF exon Ill 5' flanking region directed the transgenic 
expression of CAT in tissues that overlap with the endoge- 
nous expression pattern of exon III mRNA in the rat. 
5.5 kb of  BDNF Promoter IV Directs the Expression of 
Reporter Gene Preferentially in Brain and Pancreas 
Promoter IV of the rat BDNF gene is a classical G/C rich 
promoter  that  directs  the  expression  of BDNF  mRNA 
mainly outside of the nervous system with the highest levels 
in lung and heart (Timmusk et al.,  1993). Sensitive RNase 
protection analysis showed that BDNF exon IV mRNA is ex- 
pressed at low levels in all the rat tissues analyzed, except 
liver  (Fig.  2).  13  different founder lines  possessing  the 
reporter gene fused to the 5' flanking sequences of BDNF 
exon IV were analyzed (Fig. 2 and Table I). CAT activity was 
detected in 11 founder lines, showing that the percentage of 
transgene-expressing mice was  higher than for BDNF HI 
CAT. In seven founder lines, the levels were highest in the 
brain and pancreas, in two lines in the liver and in one line 
CAT levels were nearly equal in all the tissues analyzed. The 
expression pattern of BDNF IV CAT in transgenlc mice (as 
shown for one representative founder line in Fig. 2) suggests 
that the 5.5-kb of rat BDNT promoter IV region includes ele- 
ments essential for exon IV mRNA regulation in brain but 
is lacking sequences that are controlling the high level ex- 
pression of endogenous BDNF in the heart and lung. 
Expression ofBDNF I  + H CAT and III+ IV CAT in 
Transgenic Mice 
Partial recapitulation of the tissue specificity of endogenous 
BDNF mRNA expression and comparatively low transgene 
expression levels in the transgenlc mice possessing the four 
BDNF promoter constructs described above suggested that 
these  promoter  regions  of the  rat  BDNF  gene  are  not 
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Promoters I and II and promoters HI and IV are adjacent in 
the genome and display similar regulation patterns during 
brain  development,  suggesting  the  existence  of  shared 
regulatory sequences (Tmunusk et al., 1994a). We therefore 
decided to generate two new BDNF constructs, designated 
BDNF I  +  1I CAT and BDNF HI +  IV CAT (Fig.  1). The 
promoter region of BDNF I  +  II CAT consists of a 9.5-kb 
genomic fragment including exons I and II with their splice 
donor sites and the flanking regions. The promoter region of 
BDNF HI +  IV CAT contains a 9-kb genomic fragment in- 
eluding exons HI and IV with the flanking regions. Several 
studies have shown that transgene constructs that include SV 
small t intron downstream of coding sequences are not op- 
timal for expression, while inclusion of  generic introns in the 
constructs increases transgene expression in mice (Brinster 
et al., 1988; Choi et al., 1991; Palmiter et al., 1991). In addi- 
tion, the requirement of intragenic regulatory elements for 
tissue-specific and regulated expression has been described 
for several genes, including neural-specific ones (Vidal et 
al.,  1990; Beaudet et al.,  1992; Belecky et al.,  1993; Van- 
selow et al., 1994; Zimmerman et al., 1994). We, therefore, 
decided to include BDNF mini-introns and 3' UTR in the 
constructs  (Fig.  1).  Except for the promoter regions  and 
splice donor sites, both these constructs also contain 0.7 kb 
of BDNF coding exon 5' sequence with splice acceptor site 
and CAT coding sequence. The SV-40 polyadenylation sig- 
nals  downstream  of the  CAT  gene were replaced by  rat 
BDNF genomic region covering the 3' UTR of the 4.2-kb 
mRNA and 0.1 kb of additional downstream sequences. The 
transgene expression was analyzed in seven different brain 
regions:  cerebral cortex, hippocampus,  cerebellum, stria- 
turn, thalamus/hypothalarnus, midbrain, and brainstem. The 
analyzed nonneural tissues were the same as for the four 
transgenic constructs described above, except that expres- 
sion was not analyzed in salivary gland. 
Figure 3. Expression of  BDNF I + II CAT (CATI + II) and BDNF 
HI + IV CAT (CAT  III + IV ) in the different brain regions and non- 
neural tissues of  transgenic mice of  representative founder lines. 0.1 
nag of  protein extract was analyzed in each line by CAT assay. Sam- 
pies were incubated for 2 h at 37"C. 
BDNF I  + H CAT Directs High Level 
Expression of the Reporter Gene in the Brain and 
Thymus of Transgenic Mice 
Nine founders possessing the BDNT I  +  II CAT were ob- 
tained and bred to establish F1 transgenic lines to study the 
expression and regulation of  this promoter construct in brain 
and peripheral tissues (Tables I and II and Fig. 3). All the 
nine lines expressed high level of CAT activity in the brain. 
In the thymus, CAT activity was always 5-10-fold lower (Ta- 
ble I and Fig. 3). In seven founder lines, CAT was also ex- 
pressed in the lung with levels significantly lower than in the 
thymus.  In  the brain,  the  measured  CAT  activities  were 
Table II. CAT  Activity in Different Brain Regions and the Levels of CAT  mRNA in the Hippocampus of  Transgenic Mice 
Possessing BDNF I + II CAT  and BDNF III + IV CAT  Fusion Genes 
CAT activity 
BRAIN REGION 
CAT mRNA  x  100% 
Founder line  CTX  HIP  CBL  STR  THA  MID  STE  BDNF mRNA 
I+II 
P4  ++  +++ 
PI1  +  ++ 
Q2  +  +++ 
Q4  +++  +++ 
Q6  ++  ++ 
Q9-1  +  +  + 
Q9-2  ++  +++ 
Qll  +  + 
m+IV 
X7  +  + 
Y3-1  +++  +++ 
Y3-2  +++  +++ 
Y7  +++  +++ 
Z1  (+)  +++ 
Z8  ++  ++ 
+  +  +++  +++  ++  200-300% 
+  nt  nt  nt  +  nt 
+  +  +++  +++  ++  15-40% 
+  + +  + +  + +  + +  50-100% 
+  nt  nt  nt  +  nt 
++  +  ++  +++  ++  <5% 
+  + +  + +  + +  +  25-40% 
(+)  +  (+)  +  (+)  <5% 
-  -  (+)  +  -  <5% 
++  +++  +++  +++  +++  15-30% 
(+)  +++  +++  +++  ++  10-20% 
-  +++  +++  +++  +++  300--400% 
-  (+)  + +  + +  +  20-30% 
++  +++  ++  ++  +++  20-30% 
Average conversion of [14C]chloramphenicol  per 0.1 rag protein during 2 h reaction at 37°C in the expressing founder lines: (+), <1% conversion; +,  1-5 %; 
++,  5-25%;  +++,  >25%. 1 +  lland I11 +  IV, BDNF-CAT fusion genes BDNF I  +  1I CAT and BDNF HI +  IV CAT, repectively; nt, not tested; CTX, 
cerebral cortex; HIP, hippocampus; CBL, cerebellum; STR,  striatum; THA, thalamus and hypothalumus; MID, midbrain; STE, brainstem. 
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I CAT and BDNF II CAT. 
CAT activity was analyzed in seven different  brain regions 
(Table II and Fig. 3). The expression patterns varied slightly 
from one founder line to another, but in most of them, the 
highest levels were seen in the hippocampus, midbraln, thai- 
amus/hypothalamus, and cerebral cortex. Lower CAT activ- 
ity was detected in the brainstem and the lowest in the stria- 
turn and cerebellum. In the rat brain, the highest levels of 
endogenous BDNF exon I  mRNA, transcribed from pro- 
moter I, were seen in the hippocampus and cerebral cortex, 
and lower levels were present in the other brain regions 
(Timmusk et al., 1994a, b). In the cerebellum and striatum, 
exon I mRNA was not detected. BDNF exon H transcripts, 
synthesised from promoter  H,  are  expressed  throughout 
the rat brain,  with the highest levels in cerebellum, hip- 
pocampus, and midbrain RNA (Timmusk et al., 1994a, b). 
The transgene expression pattern  of BDNF  I  +  H  CAT 
recapitulated that of endogenous rat BDNF  mRNA tran- 
scribed from promoters I and H of rat BDNF gene with only 
two minor differences: a lower expression of  transgene in the 
cerebellum and a higher expression in the striatum (Table IT). 
Endogenous  mouse  BDNF  mRNA  and  transgenlc  CAT 
mRNA were quantified in the hippocampus of transgenlc 
animals by RNase protection using known amounts of sense 
BDNF and CAT mRNA, respectively. The results revealed 
that in several founder lines the transgene is expressed with 
levels comparable (founder fines Q4, Q2, and Q9-1) or up 
to threefold higher (founder line P4) than the endogenous 
mouse BDNF mRNA (Table ID. These results clearly show 
that the rat BDNF genomic region of  BDNF I +  II CAT con- 
struct directs  high level tissue-specific expression of the 
reporter gene in transgenic mice. 
BDNF III + IV CAT Is Expressed at High Levels in 
the Brain of Tmnsgenic Mice 
Six different transgenic mice lines with BDNF HI + IV CAT 
were obtained and the offspring analyzed as shown in Tables 
I and II and illustrated in Fig. 3. In all these founder lines, 
transgene expression was highest in brain followed by thy- 
mus. Lower levels of CAT activity were seen in the lung of 
five transgenic lines, in the kidney of  three lines, in the heart, 
pancreas and muscle of two lines, and in the spleen, liver, 
and testis of one line.  In the rat heart and lung,  BDNF 
mRNA is predominantly expressed from promoter IV of the 
BDNF gene and the total levels are comparable with BDNF 
mRNA in the brain. The results revealed that BDNF HI + 
IV CAT recapitulated the endogenous BDNF expression in 
the lung but not in the heart. 
Analysis of CAT activity expression patterns in different 
brain  regions of transgenic mice revealed that it was ex- 
pressed throughout the brain with only small differences in 
the expression levels.  In the cerebellum, CAT activity was 
absent or significantly lower. Quantification of RNA showed 
that in the hippocampus, CAT mRNA levels were compara- 
ble (founder lines Z1, Z8, Y3d, and Y3-2) or higher (founder 
line  YT)  as  compared  to  the  endogenous mouse BDNF 
mRNA levels determined in the same animals. BDNF exon 
HI mRNA, that is transcribed from promoter m  of the rat 
BDNF gene, has the most restricted expression pattern in the 
rat brain having highest levels in the cerebral cortex and hip- 
pocampus  and  5-10-fold  lower  levels  in  the other  brain 
regions. BDNF exon IV mRNA is expressed in all rat brain 
regions, except striatum, without significant differences in 
the levels (Tunmusk et al.,  1994a,  b).  Comparison of rat 
BDNF expression patterns with that of BDNF IlI+ IV CAT 
in transgenic mice showed that the transgene is expressed in 
a similar manner to the rat BDNT mRNA transcribed from 
promoters Ill and IV. The minor differences from the endog- 
enous pattern were the expression of transgene in the stria- 
turn and lower levels of expression in the cerebellum. 
5.3 kb of the Y Sequence of  BDNF Exon IV Is 
SuffJcient to Direct Lesion-induced Expression  of CAT 
in the Sciatic Nerve 
BDNF mRNA has been shown to be induced in the distal 
segment of az.otomized sciatic nerve (Meyer et al., 1992) by 
selective upregulation of exon IV mRNA levels (Funakoshi 
et al., 1993).  To explore the possibility that the induction is 
caused by differential activation of BDNF promoter IV we 
studied if axotomy of sciatic nerve induces CAT expression 
Figure 4. Expression of  BDNF IV CAT in axotomized  sciatic nerve 
of A2 founder line. (A) Time course of CAT activity changes in the 
distal segment of  transect~ sciatic nerve. (B) CAT activities, CAT 
mRNA, and mouse BDNF mRNA (codin~ exon) in different seg- 
ments of  the sciatic nerve 14 d after lesion. 0.1 mg of  protein extract 
was analyzed in each line by CAT assay. Samples were incubated 
for 2 h at 37°C. (B) 10 rag of total RNA was An~yzed  by RNase 
protection assay using cRNA probe specific for CAT or mouse 
BDNE CTR, control sciatic nerve; PRX, proximal segment of the 
transected sciatic nerve, DIS, distal  segment of the  transect~ 
sciatic nerve. 
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nerves of mice were transected and CAT activity was deter- 
mined in the distal part of the lesioned nerve at different time 
points  after  operation  (Fig.  4  A).  In  the  intact  sciatic 
nerve,  CAT activity was  low  with  levels only marginally 
above the detection limit. An increase in CAT activity was 
seen 1 wk after lesion and the levels were fivefold higher 2 
and 3 wk after lesion (Fig. 4 A). This time course of trans- 
gene expression mimics exactly the delayed induction of rat 
BDNF mRNA after sciatic nerve lesion. 
CAT activity and CAT mRNA levels were analyzed in the 
distal and proximal part of the transected sciatic nerve 2 wk 
after lesion (Fig. 4 B). In the distal part, both CAT activity 
and CAT mRNA were upregulated. In the proximal segment, 
only CAT activity was enhanced,  indicating that it is not a 
transcriptional regulation  and could be caused  by transport 
and accumulation of CAT protein. Similar results were ob- 
tained with mice from two different lines of the same con- 
struct. As the regulation of mouse BDNF mRNA in this ax- 
otomy model has not been reported, we also determined the 
mouse BDNF mRNA levels in the same samples (Fig. 4 B). 
Endogenous mouse BDNF mRNA was increased predomi- 
nantly  in  the  distal  segment of axotomized sciatic nerve. 
These data demonstrate that the 5.5-kb of BDNF exon IV the 
5' sequence is sufficient to direct correctly spatiotemporally 
regulated expression of reporter gene in the lesioned sciatic 
nerve. 
To study if the proximal region of promoter IV is sufficient 
to confer the axotomy-induced expression of reporter gene 
in sciatic nerve, transgenic mice possessing BDNF IV prox 
CAT (Fig. 1) were generated and the offspring analyzed. This 
BDNF-CAT fusion gene is a 4.6-kb 5' deletion of BDNF IV 
CAT. CAT activity was not induced in the axotomized sciatic 
nerve of any of the six different founder lines analyzed (data 
not shown).  These results indicate that the regulatory se- 
quences involved in the induction of BDNF expression in the 
lesioned sciatic nerve are located in the distal part of BDNF 
promoter IV in the region between 0.9 and 5.5 kb upstream 
from the 3' end of exon IV. 
Table III. Induction of CAT  Activity and CAT  mRNA in 
Transgenic Mice with Different BDNF-CAT  Fusion Genes 
3 h after KA Treatment or 4 h after SD Caused by 
Application of  KCl 
Kainate induction  SD induction 
CAT  CAT  CAT  CAT 
activity  rnRNA  activity  rnRNA 
Reporter 
construct  HIP  CTX  HIP  CTX  CTX  CTX 
I  0/6  0/6  nd  nd  nt  nt 
II  0/5  0/5  nd  nd  nt  nt 
Ill  0/5  0/5  lad  rid  nt  nt 
IV  0/6  0/6  2/2  2/2  0/2  1/2 
I  +  lI  1/6  0/6  3/3  2/2  0/2  1/2 
HI  +  IV  1/4  1/4  4/4  4/4  0/1  1/1 
Numeral values (positive/analyzed)  present the fraction  of animals where the 
induction of CAT expression  was observed. I, 11, IN, IV, I + n, and III+ 
IV, BDNF-CAT  fusion genes BDNF I CAT, BDNF n CAT, BDNF HI CAT, 
BDNF IV CAT, BDNF I + II CAT, and BDNF HI + IV CAT, repectively; 
rid, not detected; nt, not tested; HIP, hippocampus; C/X, cerebral  cortex. 
of BDNF HI CAT and the induction was caused by preferen- 
tial usage of promoter HI. In all the analyzed founder lines 
of BDNF I  +  II CAT and BDNF HI +  IV CAT, the levels 
of CAT mRNA were induced three- to sixfold in the hip- 
pocampus and cerebral cortex through preferential usage of 
BDNF CAT Fusion Genes Are Regulated by Kainate 
and KC! Depolarization in the Transgenic Mice Brain 
KA has been shown to induce BDNF mRNA levels in the 
adult  rat hippocampus and  cerebral  cortex  (Zafra et  al., 
1990; Ballarin et al.,  1991),  and the induction is mediated 
predominantly by promoters I and m  of the rat BDNF gene 
(Tunmusk et al.,  1993).  Therefore, we studied the expres- 
sion of BDNF-CAT fusion genes in the adult mice brain 3 
and 6 h after systemic injection of KA. Kainate did not up- 
regulate CAT activity in the hippocampus and cerebral cortex 
of any of the transgenlc founder lines possessing BDNF I 
CAT, BDNF 1I CAT, or BDNF HI CAT (Table 111). The ex- 
pression levels of reporter gene in these transgenlc mice, de- 
tected by CAT assay, were very low (Table I), and transgene 
mRNA could not be detected by RNase protection analysis. 
In transgenic mice with BDNF IV CAT, KA did not induce 
CAT activity, but in the two different founder lines analyzed, 
marked increases (eight- and fourfold) of CAT mRNA were 
seen in the hippocampus and cerebral cortex, as analyzed by 
RNase protection assay (Table HI). The promoter region of 
BDNF IV CAT is a  1-kb 3' extension of the promoter region 
Figure 5. Expression of  total CAT mRNA and CAT mRNA contain- 
hag different transgenic  5' exons of rat BDNF gene  in the hip- 
pocampus and cerebral cortex of transgenic mice 3 h after kainic 
acid treatment or 4 h after repeated episodes of spreading depres- 
sion by KCI application. (,4) Q4 founder line of  BDNF I + II CAT. 
(B) Y7 founder line of BDNF Ill +  IV CAT. mRNA expression 
was analyzed by RNase protection assays as described in Materials 
and Methods. yeast, Yeast tRNA. 
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toradiograms  of in situ hybridization showing the 
expression  of CAT  mRNA  and  mouse  BDNF 
mRNA in the brain of control (A, C, and E) and 
kainic acid treated transgenic mice (B, D, and F). 
Coronal sections were hybridized to cRNA probes 
specific for CAT (A-D) or mouse BDNF coding 
exon (E and F). (A, B, E, and F) P4 founder line 
of I  +  II CAT transgenic mouse.  (C and D) Y7 
founder line of HI +  IV CAT transgenic mouse. 
dg, Dentate gyrus; CA/and CA3, pyramidal layers 
CA1 and CA3 of  the hippocampus; hi, hilar  region 
of the hippocampus; pit, piriform cortex. 
transgenic BDNF exons I and HI, respectively (Table HI and 
Fig. 5), that resembles the induction of rat BDNF mRNA. 
In contrast to this, CAT activity was induced (1.5-fold)  only 
in the hippocampus of one of the analyzed lines with BDNF 
I  +  II CAT. In transgenic mice possessing BDNF HI +  IV 
CAT, twofold increases of CAT activity were seen only in the 
hippocampus of Y7 and in the cerebral cortex of ZI founder 
line (Table IID. 
Spreading depression (SD), caused by KCI depolarization 
of cortical neurons, has been shown to induce BDNF mRNA 
in the rat cerebral cortex (Kokaia et ai., 1993). Next, we in- 
vestigated if SD increases CAT expression in the cerebral 
cortex of transgenic lines where transgene induction by KA 
was seen. In one out of two different analyzed lines of BDNF 
I +  II CAT and BDNF IV CAT, KC1 depolarization increased 
CAT mRNA in the cerebral cortex through preferential usage 
of promoters I and HI, respectively (Table HI and Fig.  5). 
Induction of CAT mRNA was also analyzed and observed in 
one founder line of BDNF HI +  IV CAT and it was predomi- 
nantly mediated by promoter HI (Table HI and Fig. 5). The 
transgene mRNA levels after KC1 depolarization were up to 
eightfold higher than in control animals, but no changes were 
seen in the CAT activities.  These results demonstrate that 
CAT mRNA transcribed  from BDNF promoter constructs 
was regulated in the transgenic mouse brain by two different 
types of neuronal activation in a manner similar to the regu- 
lation of rat BDNF mRNA in the same experimental models. 
Transgenic Expression of  BDNF I  + H CAT 
and BDNF III + IV CAT in the Mouse Brain Is 
Neuron-specific and Overlaps with the Basal and 
Kainate-induced Expression Pattern of  Endogenous 
Rat BDNF mRNA 
The founder lines of BDNF I  +  II CAT and HI +  IV CAT 
that expressed the reporter gene at the highest levels (P4 and 
Y7, respectively) were used to analyze the transgene expres- 
sion in the brain of control and and KA-treated animals by 
in situ hybridization using 3sS-UTP labeled cRNA probe of 
CAT coding sequence. To check if the KA treatment had in- 
Figure Z CAT mRNA expression in the hipIxx:mnpus of P4 founder line of I  +  II CAT. Shown are emulsion autoradiograms  obtained 
after hybridization of coronal sections from adult control transgenic brain or from transgenic animals 3 h after kaim'c acid trea~nent to 
a cRNA probe specific for CAT. Dark-field photomicrographs  of the hippocampus are shown above. Note the sharp decrease of labeling 
at the end of CA3 region in the kainate-treated animal. Below are presented bright-field photomicrographs of higher magnification showing 
labeled neurons in CA1, CA3, and hilar region and in the granular  layer of dentate gyrus, respectively. Note that some of the neurons 
have greater intensity of labeling than neighboring ones in the CA3 and briar regions of both control and kainate-treated animals. Note 
also that in contrast to the induction of CAT mRNA by kainate in the CA3, hilus, and dentate gyrus there is no increase in the grain density 
in the neurons of CA1 region. 
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same  brain  were  also  hybridized with  a  mouse  BDNF- 
specific probe (coding exon). BDNF mRNA was induced in 
both of the analyzed animals and the distribution of BDNF 
in the brain of the analyzed animal of P4 founder line is 
shown in Fig. 6, E and E 
The transgenic line P4, expressing the BDNF I +  II CAT, 
showed the highest levels of CAT mRNA in the pyramidal 
layer of CA3  and in the hilar region of the hippocmnpus 
(Fig. 6 A). Labeling was also seen in the granular layer of 
dentate gyrus, regions CA1 and CA2, external layers of the 
cerebral cortex, and in the piriform cortex. Lower levels of 
CAT mRNA were detected in other brain regions. Different 
neurons of the same region expressed the transgene at differ- 
ent levels. In the hippocampus, the granule neurons of den- 
rate  gyms and the pyramidal neurons  of CA1  and CA2 
regions were labeled in a diffuse and uniform manner that 
contrasted with the different densities of grains found in the 
neurons of CA3 and especially of the hilus (Fig. 7). 3 h after 
systemic injection of KA, more than fivefold increases were 
seen in the CA3 and hiiar region, and in the granular cell 
layer of dentate gyms (Figs. 6 B and 7). Marked increases 
(about threefold) were also seen in the external layers of the 
cerebral cortex, in the piriform cortex, and in several nuclei 
of the amygdaloid complex, such as the medial and pos- 
teromedial amygdaloid nuclei. Examination of emulsion au- 
toradiograms revealed that labeling was restricted to neu- 
rons in control and in kainate-treated animals. These results 
are in agreement with the induction of rat BDNF exon I and 
exon II mRNAs by KA, but the relative levels of the endoge- 
nous mRNA, particularly in the dentate gyrus, are higher 
(Metsis et al., 1993; Tunmusk et al., 1993). On the cellular 
level, a  differential response to KA was seen in all these 
regions. In addition to the uniform increase in the labeling 
pattern, individual cells were found to be more densely la- 
beled than neighboring ones (Fig. 7). In the internal layers 
of  cerebral cortex and in the CA1 region of  the hippocampus, 
no increase of CAT mRNA levels were seen. 
The transgenic line Y7 was used for a more detailed study 
of the expression of BDNF HI +  IV. In this founder line, the 
levels of CAT mRNA were more than threefold higher than 
the levels of endogenous mouse BDNF mRNA in the same 
animal. Several differences were seen in the BDNF ffI +  IV 
CAT expression pattern as compared to BDNF I  +  II CAT 
(Fig. 6 C). In the hippocampus, the pyramidal neurons of 
CA1, CA2, and CA3, the neurons of  hilar region, and granu- 
lar layer of dentate gyrus expressed CAT mRNA with no 
significant differences in the labeling intensities. Further- 
more, in contrast to differential induction pattern of trans- 
gene in P4 founder line of BDNF I  +  II CAT, KA induced 
the transgene levels about threefold in all these regions of the 
Y7 founder line (Figs. 6 E and 8). Similar levels of CAT ex- 
pression were observed in the layers II-VI of cerebral cortex 
and also in the piriform cortex. Moderate labeling was seen 
in other brain regions. On the cellular level diffuse, uniform 
grain density predominated in hippocampal and cortical neu- 
rons of Y7 control and kainate-treated transgenic animal and 
labeling was not seen in glial cells (Fig. 8). The transgenic 
exression of BDNF HI +  IV CAT overlapped with the en- 
dogenous expression pattern. In the rat brain, BDNF exon 
HI and IV mRNAs are expressed at relatively equal levels in 
the dentate gyms and also in the CA1, CA2, CA3, and hilar 
regions of  hippocampus. KA treatment does not elevate exon 
IV mRNA levels substantially, but it does enhance the levels 
of exon HI mRNA predominantly in dentate gyrus and CA1 
region of hippocampus and also in CA3 and hilus (Metsis et 
al.,  1993;  Timmusk et al.,  1993). 
In conclusion, both BDNF I  +  II CAT and BDNF HI + 
IV CAT expression was detected only in the neurons with a 
cellular distribution and induction pattern similar to those of 
endogenous rat BDNF promoter-specific mRNAs. 
Discussion 
In the present study, we have analyzed more than 60 different 
transgenic mice founder lines that express CAT under the 
control of  seven different  rat BDNF promoter constructs. We 
show that all four promoters of the rat BDNF gene are capa- 
ble of driving the expression of reporter gene in transgenic 
mice, but high level expression of the reporter gene in cor- 
rect neuronal populations of mouse brain was achieved only 
by using 9 kb of genomic sequences covering the promoter 
regions that lie close to each other in the geuome and by in- 
cluding BDNF minl-introns and 3' UTR in the constructs. 
We provide evidence that SD- and KA-responsive cis-acting 
elements of rat  BDNT  gene are  separated  and  that  the 
genomic region covering promoters I and II and the region 
covering promoters HI and IV have distinct KA- and SD- 
responsive sequences. We also show that 5.5 kb of BDNF 
promoter IV region directs axotomy-induced reporter gene 
expression in the sciatic nerve of  transgenic mice in a manner 
similar to the regulation of endogenous BDNF mRNA in the 
same paradigm. 
In many transgenic mouse studies, expression from the 
transgene has been found to vary among lines derived from 
different founder animals. In addition, the transgene expres- 
sion levels are not correlated with the transgene copy num- 
ber. These differences have been believed to reflect a position 
effect resulting from random integration of  the transgene into 
the mouse genome (Pnlmiter and Brinster,  1986).  Locus 
control regions are cis-acting  DNA elements that mediate 
position-indepondent and copy number-dependent expres- 
sion of genes  (reviewed in Evans  et al.,  1990).  Several 
BDNF-CAT fusion genes, such as BDNF I CAT, BDNF II 
CAT, BDNF I +  1I CAT, and BDNF HI +  IV CAT, had very 
similar expression patterns in all the different founder lines 
of the same construct, suggesting the presence of regulatory 
regions that protect the reporter gene from the cis-acting 
effects of regulatory elements flanking random sites of in- 
tegration. On the other hand, there was no strict correlation 
Figure 8. CAT mRNA expression in the hippocampus of Y7 founder line of HI + IV CAT. Shown are emulsion autoradiograms obtained 
after hybridization of coronal sections from adult control transgenic brain or from transgenic animals 3 h after kainic acid treatment to 
a cRNA probe specific for CAT. Above are shown dark-field  photomicrographs of the hippocampus. Below are presented bright-field  pho- 
tomicrographs of higher magnification showing labeled neurons in CAI, CA3, hilus, and dentate gyrus, respectively. 
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pression levels (data not shown). It is possible that a locus 
control region exists also in the BDNF gene and only part 
of it was included in these BDNF promoter constructs, ex- 
pressed in a position-independent manner, but with expres- 
sion levels that were not correlated with the transgene copy 
number. 
1Issue-specific Expression of  BDNF-CAT Fusion 
Genes in Transgenic Mice 
When fused separately to bacterial CAT gene the upstream 
regions of exons I, II, and HI of rat BDNF gene were able 
to direct the transgene expression in tissues that partially 
overlapped with the endogenous sites of particular BDNF 
promoter activities. 2.6 kb of exon I  5' flanking sequence 
recapitulated BDNF expression in the thymus, but not in the 
brain and spleen. Similarly, 4.5 kb of exon HI 5' flanking re- 
gion was insufficient to restrict transgene expression to cor- 
rect tissues,  but predominant transgenic expression in the 
brain and muscle suggests that some regulatory elements are 
present in the analyzed promoter HI sequence. And finally, 
5.5 kb of promoter IV recapitulated endogenous expression 
in the brain, but not in the heart and lung. These results sug- 
gest that cis-acting elements that are regulating the expres- 
sion of rat BDNF gene in different tissues (cell populations) 
are separated in the genome. Examples of genes for which 
similar regulation strategy is used are Thy-1, where elements 
responsible for the brain, thymus, kidney, and spleen expres- 
sion are all separated (Vidal et al., 1990), and nestin, where 
independent regulatory elements control the expression in 
the neural stem cells and muscle precursors (Zimmerman et 
ai.,  1994). An exceptional case was the 3.7-kb of the exon 
II 5' sequence, which, when linked to the reporter gene, was 
silent in the transgenic mice. This may be explained by the 
presence of  a negative control element as a neural-restrictive 
silencer element (NRSE) has been described in the SCG10 
gene (Mori et al.,  1992) and the rat type lI sodium channel 
gene  (Kraner et al.,  1992)  and a  highly homologous se- 
quence is present in the 5' region of rat BDNF exon H (Tim- 
musk et al.,  1993). Therefore, it is possible that because of 
the absence of positive neural-specific regulatory sequences 
in the BDNF promoter II construct, this NRSE is involved 
in the suppression of transgene expression. 
Neuronal-specific and high level expression of  the reporter 
gene was  achieved by introducing two new  fusion genes, 
BDNF I +  II CAT and BDNF HI +  IV CAT, into transgenic 
mice. These constructs contain 9 kb of genomic sequences 
covering the BDNF promoter regions that lie close to each 
other in the genome, and sequences of BDNF intron-exon 
splice junctions and  3' UTR.  In the brain,  no significant 
differences from the pattern of endogenous BDNF expres- 
sion were seen for either of these constructs with the excep- 
tion of higher levels of CAT in striatum and lower in cerebel- 
lum. Although the expression levels of  transgene in the same 
brain region varied from one founder line to another of the 
same construct, the highest expression was always in the hip- 
pocampus and the absolute levels were comparable, or even 
higher, than the endogenous levels of mouse BDNF mRNA. 
The cellular expression patterns were similar to those of rat 
BDNF promoter specific mRNAs. In the brain, BDNF I  + 
II CAT and BDNF HI +  IV CAT were expressed only in the 
neurons with the highest levels in the hippocampal pyrami- 
dal, granular, and hilar neurons, as well as in the cortical 
neurons.  Transgene expression was  not  detected in  glial 
cells.  In nonneural tissues,  BDNF I  +  II CAT correctly 
mimicked the expression pattern of BDNF exon I and exon 
H mRNAs, but BDNF 1II +  IV CAT transgenic expression 
was comparatively low in heart and lung, where high levels 
of BDNF mRNA are transcribed from promoters HI and IV 
in the rat. 
We cannot precisely determine which regions of BDNF 
I  +  H CAT and BDNF HI +  IV CAT were responsible for 
the high level and accurate pattern of expression in brain neu- 
rons, because 5' flanking regions, introns, and 3' UTR, not 
present in the first four analyzed BDNF constructs, were in- 
cluded in these BDNF-CAT fusion genes.  Regulatory ele- 
ments  that drive neuron-specific expression in transgenic 
mice have been shown to be located in the 5' flanking regions 
and in the intragenic regions (reviewed in Belecky, 1993; 
Beaudet,  1992).  Correct expression pattern  in transgenic 
mice has often been achieved when the entire region covering 
the gene, as well as its 5' and 3' flanking sequences, has been 
included in the transgene (Patil et al.,  1990; Kaneda et al., 
1991).  For several neural genes,  comparatively short ge- 
nomic  regions of 5' flanking sequences have been shown 
to drive the expression to all neurons, or neurons and some 
ectopic tissues, recapitulating partially the endogeneous ex- 
pression  pattern.  Furthermore,  inclusion of longer 5' se- 
quences (Vandaele et al.,  1991) or intragenic regions (Ang 
et al., 1993; Belecky et al., 1993; Vanselow et al., 1994) has 
restricted the expression to correct neurons. Similarly, the 
shorter BDNF promoter-CAT fusion genes partially recapit- 
ulated the expression of endogenous BDNF gene, but higher 
level and more precise expression patterns were achieved 
with the longest constructs. Although both BDNF I +  II and 
BDNF HI  +  IV  CAT  contained ~15  kb of genomic se- 
quences, they did not completely mimick the complex tissue- 
specific pattern of BDNF gene. Therefore, it is reasonable 
to assume that additional regulatory regions are involved in 
the regulation of the rat BDNF gene. 
5.5 kb of  BDNF Promoter IV Region Directs 
Axotomy-induced Expression of  Reporter Gene in the 
Sciatic Nerve 
Transection of the rat sciatic nerve leads to a  marked in- 
crease of  BDNF mRNA in the distal segment of nerve, prob- 
ably in Schwann cells,  which is thought to play a role in 
providing trophic support to injured peripheral nerves. The 
increase is seen only 1 wk after lesion, with progressively 
higher levels until 3 wk after lesion (Meyer et al.,  1992; 
Funakoshi et al.,  1993). Only BDNF exon IV mRNA is in- 
creased in the lesioned sciatic nerve, suggesting that the in- 
duction is caused by selective activation of BDNF promoter 
IV (Funakoshi et al.,  1993). Here, we show that 5.5 kb of 
the 5' flanking sequence of BDNF exon IV directs axotomy- 
induced expression of CAT mRNA and CAT acti~,ity in the 
sciatic nerve of two different founder lines that were ana- 
lyzed. The time course and spatial pattern of transgene ex- 
pression  were similar  to BDNF expression in rat and  in 
mouse. Both CAT and endogenous BDNF were induced pre- 
dominantly in the distal segment of sciatic nerve and the up- 
regulation was observed first at 7 d after lesion, peaking at 
2 wk, and remained elevated also 3 wk after lesion. As previ- 
ously shown, there is also a marked increase of NGF mRNA 
The Journal of Cell Biology, Volume  128, 1995  196 in the nonneuronal cells of  lesioned sciatic nerve. In contrast 
to BDNF mRNA, the increase in NGF mRNA is biphasic 
with a rapid transient increase followed by a second increase 
that lasts for several weeks (Heumann et al., 1987). It has 
been suggested that the induction of NGF expression in the 
lesioned sciatic nerve is mediated by the immediate early 
gene c-fos through a functional AP-l-binding site in the NGF 
gene  (Hengerer  et al.,  1990). The delayed induction  of 
BDNF and promoter IV-CAT fusion gene suggests that c-fos 
and other transcription factors encoded by immediate early 
genes are not involved in the regulation of  BDNF expression 
after sciatic nerve transection. We have shown that adrenal- 
ectomy attenuated the increase of BDNF mRNA in the le- 
sioned nerve and that a putative binding site for the glucocor- 
ticoid receptor is present 420 bp upstream from the cap site 
of promoter IV, suggesting that glucocorticoids could be in- 
volved in the upregulation of BDNF mRNA (Funakoshi et 
al., 1993). In this study, we show that 0.9 kb of the exon IV 
5' sequence is not sufficient to mediate the induction of the 
reporter gene in lesioned sciatic nerve, suggesting that this 
putative binding site for the glucocorticoid receptor is not in- 
volved in the regulation of BDNF induction in this experi- 
mental model. Work is in progress to determine which par- 
ticular sequence elements are involved in the regulation of 
BDNF expression in lesioned sciatic nerve. 
Regulation of the Expression of BDNF-CAT Fusion 
Genes in the Hippocampus and Cerebral Cortex after 
KA Seizures and KCl-mediated Depolarization 
BDNF mRNA levels in the hippocampus and cerebral cortex 
of adult rat brain have been shown to be markedly but tran- 
siently induced by several stimuli such as seizures induced 
by administration ofKA (Zafra et al., 1990; Ballarin et al., 
1991; Dugich-Djordejevic et al., 1992a, b), pentylentetrazol 
(Humpel et al., 1993), pilocarpine  (Berzaghi et al., 1993; 
Metsis et al., 1993) focal electrolytic lesions (Isackson et al., 
1991), kindling  after electric  stimulation  (Ernfors  et al., 
1991), ischemic insults and insulin-induced hypoglycemic 
coma (Ernfors et al.,  1991; Lindvall et al., 1992; Comelli 
et al., 1993), and cortical SD induced by application of KCl 
(Kokaia et al., 1993). These data have led to the hypothesis 
that BDNF protein could play a neuroprotective role after 
brain insults. 
We investigated if the expression of BDNF-CAT fusion 
genes is induced by systemic kainic acid treatment, which is 
a potent pharmacological regulator of  BDNF mRNA expres- 
sion.  CAT mRNA  was  under the detection  limit in  the 
founder lines possessing BDNF I CAT, BDNF II CAT, and 
BDNF Ill CAT. All the other BDNF promoter constructs 
analyzed, BDNF IV CAT, BDNF I  +  II CAT, and BDNF 
Ill  +  IV  CAT, directed  kainate-inducible  expression  of 
reporter gene mRNA in the transgenic mice by preferential 
usage of exons I and Ill in these constructs. The relative in- 
creases of transgene mRNA varied in different founder lines 
of  the same construct but were always smaller than for partic- 
ular BDNF exon mRNAs. Striking differences were seen in 
the regional distribution of increases of CAT mRNA after 
treatment with kainic acid. In the hippocampus, transgene 
mRNA transcribed  from BDNF I  +  II CAT of P4 founder 
line was increased in the hilar region,  in the granular cells 
of  dentate gyrus and in the CA3 region. No significant induc- 
tion was observed in the CA1 region. Rat BDNF exon I and 
exon 11 mRNAs are induced in similar hippocampal neuronal 
populations, but with a more marked relative increase in the 
granular cell layer of  dentate gyrus. CAT mRNA transcribed 
from BDNF HI + IV CAT was increased in CA1, CA2, and 
CA3 regions and in dentate gyrus with no significant differ- 
ences  in the amplitude  of induction.  Rat BDNF  exon HI 
mRNA is increased in the same hippocampal neuronal popu- 
lations, but the increase is more marked in CA1 region. 
SD, caused by KCI depolarization of cortical neurons, was 
tested in those founder lines that showed a marked induction 
of transgene mRNA after KA treatment.  SD induced CAT 
mRNA expression in the cerebral  cortex of one analyzed 
founder line of BDNF Ill +  IV CAT and in one out of two 
analyzed  founder lines of BDNF IV CAT. Furthermore,  SD 
increased CAT mRNA expression in one out of  two analyzed 
founder lines ofBDNF I + II CAT, while KA induced trans- 
gene expression in both of them.  The results indicate that 
both KA- and SD-responsive cis-acting elements are present 
in the BDNF 5.5-kb sequence of BDNF IV CAT (containing 
both exon 11I and exon IV, and their 5' flanking sequences), 
and also in the BDNF genomic regions of  BDNF I + II CAT. 
As these BDNF-CAT fusion genes do not have overlapping 
BDNF sequences, it is highly likely that different signaling 
pathways, linked to the responsive cis-acting elements in the 
cluster of promoters  I and 1/, and to the sequences in the 
cluster of  promoters HI and IV, mediate the kainate induction 
of rat BDNF gene. The variation of induction of BDNF I + 
II CAT and BDNF IV CAT by KA and SD could be the result 
of  a different transgene integration site where the SD- but not 
KA-responsive cis-acting elements lost the ability to mediate 
transgene induction in one founder line, suggesting that KA 
and SD elements are different and located in different sites 
of  the sequence of  these BDNF-CAT fusion genes. Taken to- 
gether, our data suggest that (a) SD- and KA-responsive c/s- 
acting elements of rat BDNF gene are separated;  and (b) 
genomic region covering promoters I and II and genomic re- 
gion covering promoters Ill and IV have distinct KA- and 
SD-responsive sequences. 
Concerning the signaling pathways leading to the induc- 
tion of  BDNF mRNA, it has recently been shown that in cul- 
tured embryonic cortical neurons, KC1 and glutamate induce 
BDNF expression by activation of  distinct calcium channels, 
L-type voltage-sensitive calcium channels, and N-methyl-I)- 
aspartate receptors respectively (Ghosh et al., 1994). Fur- 
thermore, in cultured hippocampal neurons L-type calcium 
channels and NMDA receptors are coupled to two different 
signaling pathways that activate transcription through differ- 
ent cis-acfing regulatory elements  in  the c-fos promoter 
(Bading et al., 1993). Since KC1 and KA in this study were 
applied systemically, the induction of CAT expression was 
probably caused not only by direct activation of  one particu- 
lar glutamate  receptor,  but also by indirect  activation of 
different glutamate receptor subtypes by endogenous gluta- 
mate release that is thought to mediate the increase of  BDNF 
expression in these experimental models (Zafra et al., 1990; 
Kokaia et al., 1993). It remains to be determined to what ex- 
tent the increase of  BDNF gene expression is causally related 
to the activation of immediate-early  genes,  such as c-los, 
c-tim, zif/268, and others, in KA-mediated seizures and SD 
(reviewed in Morgan and Curran, 1991). 
KA and SD upregulated CAT mRNA levels in transgenic 
mice of  different BDNF-CAT fusion genes up to 10-fold, but 
mostly it was not paralleled by an increase of CAT protein, 
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cent]y, it was reported that the kainate-induced increase of 
BDNF mRNA was  not paralleled  by alterations of equal 
magnitude  and  distribution  of BDNF  immunoreactivity 
(Wetmore et al., 1994). The increase ofBDNF immunoreac- 
tivity was observed in restricted neuronal subpopulations of 
hippocampus, with most significant changes in the C.A3 re- 
gion, and to a lesser degree in other cortical areas. Similarly, 
it has been reported that during the acute phases of pentylen- 
tetrazol  seizures,  the increase  of BDNF mRNA levels in the 
hippocampus is not paralleled by an increase of BDNF-like 
immunoreactivity (Humpel et al.,  1993).  This discrepancy 
between the induction level of CAT (and also BDNF) mRNA 
and protein could be explained by the results obtained using 
hippocampal slice culture showing that high concentrations 
of glutamate, KA, NMDA, and quisqualate inhibit neuronal 
protein synthesis by ~90%  (Vornov and Coyle,  1991). We 
cannot rule out that CAT protein, like  BDNF protein, is in- 
duced only in some neuronal populations, and that the CAT 
assay is not a suitable method to detect these subtle changes. 
Finally, the finding that axotomy  induced CAT activity  in 
transgenlc  lines  with  BDNF  IV  CAT  suggests  that only 
moderate BDNF mRNA induction by focal lesions,  like ax- 
otomy, or by more physiological  stimuli like light (Castn~n 
et al., 1992), long-term potentiation (Patterson et al., 1992; 
Castn~n et al.,  1993),  improved spatial memory,  and en- 
riched environment (Falkenberg et al., 1992),  may result in 
elevated BDNF protein levels. 
Taken together, this study is one of the first steps towards 
the understanding of the regulatory mechanisms governing 
BDNF  gene  expression.  Our results  show that the mul- 
tipromoter structure of the BDNF gene supports neuronal 
function through a complex regulation of gene expression in 
different tissues  and cell  populations.  The transgenic mice 
with the various BDNF-CAT fusion genes provide the oppor- 
tunity to study the relative contributions of BDNF promoters 
and their particular sequence  elements in the regulation of 
BDNT gene expression  during development,  as well as in 
different lesion models or after neuronal activation. Finally, 
targeted expression of neurotrophins and other heterologous 
genes under the control of the described BDNF promoter 
constructs  could be used to study their function  and regula- 
tion in the nervous system and nonneural tissues. 
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